ClinicalTrials.gg
RecruitingNCT06608706KITUpdated Apr 24, 2026

The Key to Integrated Trauma Treatment in Psychosis Trial

An interventional study of Eye Movement Desensitization and Reprocessing (EMDR) for psychosis in Psychiatric Diagnosis, Schizophrenia Disorders and Psychological Trauma, Historical, sponsored by Haukeland University Hospital. Recruiting at 11 sites in Norway. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Haukeland University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

Schizophrenia spectrum disorders (SSDs) have a significant trauma etiology: trauma has been reported in 65 - 80% in this patient group and have a negative impact on prognosis. Trauma treatment is currently not offered in SSDs due to a lack of evidence. KIT is a pragmatic trial comparing the effectiveness of added trauma focused therapy, Eye Movement Desensitization and Reprocessing (EMDR) to standard treatment in SSDs.

The study will compare EMDR as add on to treatment as usual (TAU) to TAU in patients with schizophrenia spectrum disorders (SSDs). The overall aim is to examine the effectiveness of EMDR on trauma symptoms in SSDs.

Participants will receive max. 26 sessions of EMDR, and complete assessments before, during and after the course of therapy, in addition to a period of time (6 months) after therapy to examine long-term effects.

Read the detailed description

The KIT trial is a pragmatic, assessor-blinded, parallel 2-group, superiority randomized trial comparing the addition of EMDR to treatment as usual (TAU) versus waiting list (WL) and TAU for EMDR on symptoms of trauma in patients with SSDs. Participants will be randomized (1:1, block randomization by center and gender) to one of the two groups.

Aims, hypotheses, objectives:

  • The primary aim is to investigate the effectiveness of EMDR as an add-on treatment for SSDs in standard clinical practice to target trauma symptoms.
  • The secondary aim is to improve personalized therapy through the exploration of clinical stratification variables that may influence the effectiveness of EMDR.
  • The long-term aim is to guide clinical practice and, if shown to be effective, to implement EMDR for patients with SSDs.
  • The primary objective: EMDR and treatment as usual (TAU) compared to waiting list (WL) and TAU will reduce symptoms of trauma as measured by the ITQ (the International Trauma Questionnaire) in SSDs.
  • The secondary objective: Stratification variables (trauma profile e.g. type, severity, timing; gender; biomarkers of stress and immune system reactivity; digital biomarkers of autonomous stress reactivity) influence the effectiveness of EMDR.

Expected results during the project period:

  • The EMDR group will show less trauma symptoms compared to the WL control group by the end of treatment and possibly better functioning.
  • No differences for costs nor serious adverse events will emerge between the groups at the end of treatment.
  • Better outcomes are expected for trauma characterized by mild to moderate severity and later onset (e.g. related to experience of psychosis) as compared to CT (e.g. abuse and neglect).
  • Although exploratory, patients with high levels of inflammation markers and/or hyperarousal and autonomous reactivity to trauma benefit most from EMDR.

EMDR for psychosis therapists: Eighteen trial therapists are currently fully trained in EMDR for psychosis in collaboration with Dr. Varese and colleagues at Manchester University, and receive monthly supervision. At least 24 more will be trained by early 2025. Assuming some therapist drop-out, 40 trial therapists will be recruiting SSD patients from their patient lists.

Assessments: Assessments will be performed for both groups by blinded research personnel at baseline, mid-treatment (12 weeks), end of treatment (6 months), 6- and 12-months post randomisation after end of treatment, in addition to digital patient feedback every 2 weeks from baseline to end of treatment at 6 months. The follow-up period after end of treatment is to examine long-term effects.

Eligible participants will be given initial information (verbal, web page, pamphlets) by the trial therapists, and then verbal and written information by research staff and asked for informed consent to partake in the trial. Primary outcome will be measured by the ITQ, a validated measure assessing reliable and clinically significant treatment-related change in trauma symptoms, including symptoms of PTSD and complex PTSD, used in outpatient clinics in Norway. Demographic and clinical information will be supplemented by clinical records and national health registers (e.g. Legemiddel-registeret, Kontroll og utbetaling av helserefusjoner, Kommunalt pasient og bruker-register, Norsk pasientregister, Nasjonalt kvalitetsregister for behandling i psykisk for voksne). Healthcare costs (e.g. use of all health care, health related financial support, transportation) will be captured by the study nurses at each assessment point and through health registers.

Patients' experience of trauma symptoms, working alliance and recovery will be assessed through Norse Feedback digital self-report. The digital assessment of the main outcome trauma symptoms (ITQ) will be captured every 2 weeks to closely monitor symptom fluctuations, while recovery and therapist alliance follow the time points of the study nurse assessments. This decentralised assessment is deemed particularly suitable in mental health. Assessment of somatic status (heartrate, weight, blood pressure) will be supplemented by blood samples of inflammation markers (CRP, IL6 and S-cortisol) and blood samples to the Bergen Psychosis Biobank for later analysis (e.g. IL18). The digital biomarkers heart rate variability, respiration rate (electro- cardiography/photoplethysmography), activation/ movement (actigraphy) and skin conductance (electrodermal activity) will be measured in-session by BioPoint wristworn biosensor. Trial therapists will rate fidelity, patient safety related adverse events (AE) and symptom exacerbation after each session, and variables facilitating implementation before/after trial participation. For symptom-specific items on suicidality, psychosis, substance abuse and hospitalisations. A sub-group of 30 patients will be asked about their experience of the therapy with a qualitative interview after treatment.

Work packages: Quality of assessments and analysis will be ensured by organising themes in work packages (WP) headed by national experts; WP0 Study management, WP1 Clinical outcome, WP2 Somatic status and biomarkers, WP3 Trauma characteristics, WP4 Treatment alliance and user experience, WP5 Study imple-mentation, WP6 Health economic evaluation.

Protocol adherence: Hospital Clinical Monitor will ensure protocol implementation and site responsibility. The protocol will be adhered to by all trial personnel, including trial therapists and local PIs to ensure patient safety and trial quality. There will be frequent meetings across sites and written agreements on site responsibility. All sites will use electronic report files (CRF) via Viedoc for patient case report forms.

Organization: The KIT trial is organized in Bergen Psychosis Research Group (BPRG) at Haukeland University Hospital. BPRG has extensive experience from clinical trials on SSDs (ClinicalTrials.gov IDs NCT00932529, NCT01446328, NCT03340909, NCT02597439, NCT02146547).

02

Conditions studied

  • Psychiatric Diagnosis
  • Schizophrenia Disorders
  • Psychological Trauma, Historical

Keywords

  • Psychosis
  • EMDR
  • Trauma treatment
  • Schizophrenia spectrum disorders
  • Childhood trauma
  • Psychological trauma
  • PTSD
03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 187 is above the median of 100 across 1,305 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged ≥ 16 years
  2. diagnosis of F20-29 in the ICD-10 assessed using SCID 5 CV
  3. reporting trauma \> 1 month prior to assessment
  4. being currently distressed by the reported trauma(s), i.e., ≥ 5 (from 0 = not at all, to 10 = extremely) on item 21c on the Trauma and Life Events Checklist (TALE)
  5. able and motivated for engaging in trauma focused (TF) therapy
  6. able to understand and give ; consent capacity for psychological treatment choices and consent to study procedures.

Exclusion criteria

Exclusion Criteria:

  1. primary diagnosis of substance use/alcohol dependence
  2. inability to understand spoken Norwegian
  3. organic psychosis or a neurological disorder
  4. acute state of psychosis defined as:

    1. hospitalized in an acute ward the last 6 weeks or
    2. major change in antipsychotic medication type or started/stopped antipsychotic medication last 6 weeks or
    3. other mental health crises last 6 weeks
  5. current or previous (past 6 months) TF therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
187 participants (estimated)

Study arms

  • Experimental
    Trauma-focused therapy: EMDR for psychosis and treatment as usual (TAU)

    Patients randomized to receive max. 26 sessions of EMDR for psychosis.

    Other: Eye Movement Desensitization and Reprocessing (EMDR) for psychosis

  • No intervention
    Treatment as usual (TAU) and waiting list (WL)

    Patients randomized to continue with treatment as usual (TAU) for 6 months as a waiting list (WL) control group. TAU consists of an individual combination of treatments for SSDs in line with Norwegian national guideline (e.g. medication, cognitive therapy, work training, music therapy).

Interventions

  • OtherEye Movement Desensitization and Reprocessing (EMDR) for psychosis

    EMDR aims to treat and process trauma by safely retrieving the trauma memories while taxing the working memory. EMDR targets trauma symptoms through memory reprocessing of traumatic memories, and consists of eight flexible phases: history taking/case conceptualization; preparation for memory reprocessing; assessment/identification of a target memory; desensitization/reprocessing; installation of positive cognition; body scan; closure; and re-evaluation. EMDR in the current trial has psychosis-specific adaptations including focus on psychoeducation, preparation for reprocessing and patient safety. Techniques targeting dissociation, psychotic symptoms and psychosis-related challenges are included.

06

What researchers measure

Primary outcomes

  1. Trauma symptoms

    Primary outcome is trauma symptoms as measured by the International Trauma Questionnaire. PTSD symptom scale range from 0 to 24. Higher scores indicate more sever trauma symptoms.

    Time frame: From baseline to end of treatment at 6 months.

Secondary outcomes

  1. Severity of psychosis symptoms

    Secondary outcome is psychosis symptoms as measured by the The Positive and Negative Syndrome Scale (PANSS), which ranges from 30 to 210, with higher scores indicating more severity.

    Time frame: From baseline to end of treatment at 6 months.

  2. The rate of autonomic arousal during trauma processing

    Digital biomarkers measured with BioPoint wrist-worn device. Physiological stress reactivity is recorded non-invasively and continuously, offering an especially suitable means for monitoring objective physiological responses. Real-time assessments of hyperarousal, autonomic and somatic reactivity, and stress reactivity (including heart rate variability, skin conductance, respiration, and actigraphy) will be administered during EMDR sessions.

    Time frame: Baseline to end of treatment at 6 months.

  3. Inflammation

    Measure of inflammation markers (CRP, IL6) using blood samples

    Time frame: Baseline and end of treatment at 6 months

Other outcomes

  1. Clinical stratification by trauma type and severity measured by the Childhood Trauma Questionnaire

    Trauma type and severity as measured by the Childhood Trauma Questionnaire short form (CTQ-SF). CTQ-SF ranges from 25 to 125, with higher scores indicating more severe childhood trauma. Subscale scores range from 5-25 for the following sub scales: physical, emotional and sexual abuse, and physical and emotional neglect.

    Time frame: Baseline to end of treatment at 6 months.

  2. Adverse events

    No differences in adverse events is expected between the groups.

    Time frame: Baseline to end of treatment at 6 months.

  3. Health care costs

    No difference in health care costs is expected between the groups.

    Time frame: Baseline to end of treatment at 6 months.

  4. Clinical stratification by trauma type and severity measured by the Traumatic experiences checklist

    Severity and type of trauma measured by the Traumatic Experiences Checklist (TEC). The TEC indicates the presence of trauma on a scale from 0-29, higher scores indicating more exposure. TEC also include composite scores from 0-12 by developmental period, where higher scores indicate more severity.

    Time frame: Baseline to end of treatment at 6 months.

  5. Clinical stratification by trauma symptoms measured by the International Trauma Questionnaire

    Trauma symptoms measured by the International Trauma Questionnaire (ITQ). The ITQ ranges from 0-24 for PTSD symptoms and 0-24 for symptoms of complex PTSD, where higher scores indicate more severe symptoms. There is also a diagnostic algorithm for PTSD and complex PTSD status.

    Time frame: Baseline to end of treatment at 6 months.

07

Study locations

11 of 11 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No — This is not feasible due to Norwegian policies in clinical research.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.

Of 668 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 39 months is above that.

Counting every sponsor, half of 682 studies reached it within 29 months; a quarter within 13 and three quarters within 45.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 23, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06608706
Collaborators
Helgeland Hospital Trust, Diakonhjemmet Hospital, Helse Stavanger HF, Helse Fonna Hospital Trust, University Hospital of North Norway, Oslo University Hospital, Voss DPS Bjørkeli, Solli DPS, Betanien DPS, St. Olavs Hospital
Responsible party
Else-Marie Løberg (Principal Investigator (Professor, PhD, Psychologist), Haukeland University Hospital) — Principal investigator
First posted
Sep 23, 2024
Start date
Sep 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 24, 2026

Study contacts

Else-Marie Løberg, PhD, Professor
Contact
else.marie.loberg@helse-bergen.no
4798094420
Nina Mørkved, PhD, Assoc. Professor
Contact
nina.morkved@helgelandssykehuset.no
4792286165

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion